

EXPRESS MAIL NO. EL852794767US

PTO/SB/08A (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet

1

of

6

Complete if Known	
Application Number	09/234,208
Filing Date	January 20, 1999
First Named Inventor	Doherty
Art Unit	1642
Examiner Name	Anne L. Holleran

Attorney Docket Number

49321-1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
Ault	B1	US-2001/0014326 A1	08-16-2001	Andya et al.	
Ault	B2	US-2001/0021505 A1	09-13-2001	Morris et al.	
Ault	B3	US-2002/0146420 A1	10-10-2002	Bennett et al.	
Ault	B4	US-2002/0155527 A1	10-24-2002	Stuart et al.	
Ault	B5	US-2002/0165193	11-07-2002	Greene et al.	
Ault	B6	US-2002/0172984 A1	11-21-2002	Holland et al.	
Ault	B7	US-2003/0036179	02-20-2003	Genentech, Inc.	
Ault	B8	US-2003/0044842 A1	03-06-2003	Genentech, Inc.	
Ault	B9	US-2003/0044945	03-06-2003	Genentech, Inc.	
Ault	B10	US-2003/0055239 A1	03-20-2003	Kendall et al.	
Ault	B11	US-2003/0078222 A1	04-24-2003	Ghildyal et al.	
Ault	B12	US-4,933,294	06-12-1990	Waterfield et al.	
Ault	B13	US-5,401,638	03-28-1995	Camey et al.	
Ault	B14	US-5,464,751	11-07-1995	Greene et al.	
Ault	B15	US-5,514,554	05-07-1996	Bacus	
Ault	B16	US-5,571,894	11-5-1996	Wels et al.	
Ault	B17	US-5,578,482	11-26-1996	Lippman et al.	
Ault	B18	US-5,604,107	02-18-1997	Camey et al.	
Ault	B19	US-5,677,171	10-14-1997	Hudziak et al.	
Ault	B20	US-5,720,937	02-24-1998	Hudziak et al.	
Ault	B21	US-5,747,261	05-05-1998	King et al.	
Ault	B22	US-5,756,456	05-26-1998	Ho et al.	
Ault	B23	US-5,763,213	06-09-1998	Ho et al.	
Ault	B24	US-5,783,186	07-21-1998	Arakawa et al.	
Ault	B25	US-5,837,523	11-17-1998	Greene et al.	
Ault	B26	US-5,861,301	01-19-1999	Terman et al.	
Ault	B27	US-5,874,528	02-23-1999	Lupu et al.	
Ault	B28	US-5,910,583	06-08-1999	Marks et al.	
Ault	B29	US-5,919,764	07-06-1999	Greene et al.	
Ault	B30	US-5,985,553	11-16-1999	King et al.	
Ault	B31	US-6,015,587	11-18-2000	Hudziak et al.	
Ault	B32	US-6,020,308	02-01-2000	Boyd et al.	
Ault	B33	US-6,045,797	04-04-2000	Margolis et al.	
Ault	B34	US-6,054,561	04-25-2000	Ring	
Ault	B35	US-6,166,082	12-26-2000	Kluender et al.	
Ault	B36	US-6,174,889 B1	01-16-2001	Cockerill et al.	
Ault	B37	US-6,204,011 B1	03-20-2001	Kendall et al.	

Anne L. Holleran

6/28/2004

Aut	B38	US-6,267,958 B1	07-31-2001	Andya et al.	
Aut	B39	US-6,333,169 B1	12-25-2001	Hudziak et al.	
Aut	B40	US-6,359,115 B1	03-19-2002	Kendall et al.	
Aut	B41	US-6,375,929 B1	04-23-2002	Thomas, Jr. et al.	
Aut	B42	US-6,387,371 B1	06-14-2002	Hudziak et al.	
Aut	B43	US-6,399,063 B1	06-04-2002	Hudziak et al.	
Aut	B44	US-6,399,743 B1	06-04-2002	Majumdar	
Aut	B45	US-6,414,130 B1	07-02-2002	Doherty et al.	
Aut	B46	US-6,417,168	07-09-2002	Greene et al.	
Aut	B47	US-6,441,143	08-27-2002	Koski	

Anne L. Wallen

6/28/2004


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
AH	B48	AU-B-64135 (WO91/02062)	03-11-1991	Berlex Laboratories Inc.		
AH	B49	CA 2,042,064 (No PCT)	02-05-1991	Triton Biosciences, Inc.		
AH	B50	CA 2,055,441 (WO90/14357 A1)	11-29-1990	Genentech, Inc.		
AH	B51	CA 2,187,781 (WO95/25166)	09-21-1995	New York Univ. Med. Ctr.		
AH	B52	CA 2,260,061 (WO98/02438)	01-22-1998	Glaxo Group Limited		
AH	B53	EP 0 119 528 B1	05-13-1992	Sloan-Kettering Institute for Cancer Research		
AH	B54	EP 0 171 407 B1	11-18-1993	Imperial Cancer Research Techn. Ltd.		
AH	B55	EP 0 412 116 B1	11-29-1995	Applied Biotechnology, Inc.		
AH	B56	EP 0 444 181 B1	10-31-2001	Schering Aktiengesellschaft		
AH	B57	EP 0 474 727 B1	07-23-1997	Genentech, Inc.		
AH	B58	EP 0 491 675 A1	06-24-1992	Waterfield/ICRF Patents Ltd.		
AH	B59	EP 0 494 135 B1	04-10-1996	Oncogene Science, Inc.		
AH	B60	EP 0 600 744 B1	03-04-1998	Arizona Board of Regents		
AH	B61	EP 1 006 194 A2	06-07-2000	Triton Biosciences Inc.		
AH	B62	EP 1 114 863 A2	07-11-2001	Genentech Inc.		
AH	B63	EP 1 304 110 A2	04-23-2003	Glaxo Group Limited		
AH	B64	EP 1 308 455 A2	05-07-2003	Genentech, Inc.		
AH	B65	WO 00/27426	05-18-2000	Genentech, Inc.		
AH	B66	WO 01/89566	11-29-2001	Genentech, Inc.		
AH	B67	WO 02/09091	11-14-2002	Glycosciences Ltd.		
AH	B68	WO 02/11677	02-14-2002	Imclone Systems Incorporated		
AH	B69	WO 03/025141	03-27-2003	Intergenetics Incorporated		
AH	B70	WO 03/035843	05-01-2003	Buck Institute for Age Research		
AH	B71	WO 2003/060071 A3	07-24-2003	Human Genome Sciences, Inc.		
AH	B72	WO 85/03357	08-01-1985	ICRF Patents Ltd./Yeda Research & Development		
AH	B73	WO 89/10412	11-2-1989	Applied Biotechnology, Inc./Whitehead Institute for Biomedical Research		
AH	B74	WO 90/14357	11-29-1990	Genentech, Inc.		
AH	B75	WO 91/02062	02-21-1991	Triton Biosciences		
AH	B76	WO 91/05264	04-18-1991	Oncogenetics Partners		
AH	B77	WO 92/14748	09-03-1992	American Cyanamid Company		
AH	B78	WO 92/20798	11-26-1992	Genentech, Inc.		
AH	B79	WO 93/14124	07-22-1993	Helsinki University Holding, Ltd.		
AH	B80	WO 95/25168	09-21-1995	New York University Medical Center		

Ally	B81	WO 95/30331	11-16-1995	Trustees of the University of Pennsylvania		
Ally	B82	WO 98/02438	01-22-1998	Glaxo Group Limited		
Ally	B83	WO 98/23782	06-04-1998	Regents of the University of California		
Ally	B84	WO 99/19732	04-22-1999	Abbott Laboratories		
Ally	B85	WO 99/39729	08-12-1999	Genentech, Inc.		

Examiner Signature	<i>Anne C Holleran</i>	Date Considered	6/28/2009
--------------------	------------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


(Use as many sheets as necessary)

Sheet	5	of	6	Attorney Docket Number	49321-1
-------	---	----	---	------------------------	---------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ALH	B86	DOHERTY et al., The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. 96:10869-10874, 1999	
ALH	B87	VALERON et al., Quantitative analysis of p185 ^{HER-2/neu} protein in breast cancer and its association with other prognostic factors. Int'l. J. Cancer (Pred. Oncol) 74:175-179, 1997	
ALH	B88	ZEBRECKY et al., The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem. 266(3):1716-1720, 1991	
ALH	B89	PRESS et al., Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:4960-4970, 1993	
ALH	B90	REITER et al., A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucl. Acids. Res. 24(20):4050-4056, 1996	
ALH	B91	ROSS et al., The Her-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. <u>Stern Cells</u> , Alphamed Press, Dayton, OH US, Vol. 16 No. 6, pages 413-428, 1998	
ALH	B92	SCOTT et al., A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells, Molec. And Cellular Biol. 13(4): 2247-2257, 1993	
ALH	B93	YAMAMOTO et al., Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor, Nature 319:230-234, 1986	
ALH	B94	COUSSENS, et al., Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with <i>neu</i> Oncogene, Science 230:1132-1139, 1985	
ALH	B95	AZIOS et al., Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of	

Anne L. Holloran 6/28/2004



2004		HER-3 by HER-2 and blocks EGF activation of the EGF receptor, Oncogene 20:5199-5209, 2001	
	B96	AIGNER et al., Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation, Oncogene 20:2101-2111, 2001	
<i>Alt</i>	B97	BASELGA and MENDELSON, The epidermal growth factor receptor as a target for therapy in breast carcinoma, Breast Cancer Research and Treatment 29:127-138, 1994	
<i>Alt</i>	B98	BASELGA et al., Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies, Journal of the national Cancer Institute, vol. 85, No. 16, August 18, 1993	
<i>Alt</i>	B99	FAN et al., Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts, Cancer Res. 53:4637-4642, 1993	
<i>Alt</i>	B100	GLEASON et al., Platelet Derived Growth Factor (PDGF), Androgens and Inflammation: Possible Etiologic Factors in the Development of Prostatic Hyperplasia, J. Urol. 149:1586-1592, 1993	
<i>Alt</i>	B101	PEGRAM et al., The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer, Chapter 4: Clinical Development of Herceptin Therapy for Breast Cancer, pp. 58-75	
<i>Alt</i>	B102	PREWETT et al., Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin, International Journal of Oncology 9:217-224, 1996	
<i>Alt</i>	B103	REITER and MAIHLE, A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor, Nucl. Acids Res. 24:20) 4050-4056, 1996	
<i>Alt</i>	B104	ROSS and FLETCHER, The HER-2/new Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor and Target for Therapy, Stem Cells 16:413-428, 1998	

Examiner Signature	<i>Anne L. Hallinan</i>	Date considered	6/28/2004
--------------------	-------------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.